Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 100 systematic review(s)/meta-analysis(es). ^[1-98]
• In patients with meningiomas, the mean progression-free survival (PFS) was 19.1 ± 4.7 months, and the mean overall survival (OS) was 23.9 ± 8.4 months, with PFS-6 at 0.80 (95% CI (confidence interval): 0.64-0.89), PFS-12 at 0.66 (95% CI: 0.46-0.82), PFS-24 at 0.25 (95% CI: 0.16-0.37), OS-6 at 0.89 (95% CI: 0.80-0.96), OS-12 at 0.86 (95% CI: 0.65-0.95), and OS-24 at 0.48 (95% CI: 0.16-0.82); response rate was 0.33 (95% CI: 0.14-0.60).
• In glioblastoma multiforme (GBM), adding bevacizumab to temozolomide and radiotherapy did not increase OS (OR (odds ratio) 0.843, 95% CI: 0.615-1.156, P = 0.290) or PFS (OR 0.829, 95% CI: 0.561-1.224, P = 0.346).
• For epithelial ovarian cancer, the combination of bevacizumab with carboplatin and paclitaxel improved PFS, with an HR of 0.73 (95% CI: 0.58-0.92; p = 0.008), though OS data were not specified. Additionally, this combination therapy is associated with an increased incidence of hypertension, non-CNS bleeding, thromboembolic events, gastrointestinal perforation, pain, and proteinuria.
• In non-small-cell lung cancer (NSCLC), treatment with pemetrexed and bevacizumab improved OS (HR 0.87, 95% CI: 0.76-0.99; P = 0.03) and PFS (HR 0.63, 95% CI: 0.55-0.72; P < 0.00001). The addition of these drugs is also linked to a higher frequency of grade ≥3 adverse events: OR 2.15 (95% CI: 1.62 to 2.84; P < 0.00001).
• For metastatic colorectal cancer (mCRC), trifluridine-tipiracil with bevacizumab shows a higher rate of neutropenia (RR 1.38; 95% CI: 1.19-1.59; p = 0.00001) and a lower risk of anemia (RR 0.60; 95% CI: 0.44-0.82; p = 0.001).
• Cervical cancer treatment with bevacizumab and radiotherapy is linked to an increased risk of gastrointestinal/genitourinary toxicities.
• For meningiomas, the population was predominantly male (47.9%), with relevant characteristics including WHO grade II/III status, presence of neurofibromatosis, and history of prior resection.
• For chordomas, tumor sites included sacral, clivus, and lumbar spine, with prior treatments involving surgery, radiotherapy, and systemic treatments.